Tenderwize
Wróć do wyszukiwania

Drug discount agreements from 01.07.2025 for various active ingredients under an open-house procedure

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline Apr 26, 2027 · 243 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.07.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

30/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

30 / 100

Złożoność

20 / 100

Czynniki ryzyka

The buyer reserves the right to conclude exclusive contracts during the term, which will suspend these open-house agree...

No guaranteed purchase volumes; actual revenue depends on prescriptions and market share.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Provide drug discount agreements for the listed active ingredients and combinations.
  • Contract duration up to 24 months from earliest start date 01.07.2025.
Pokaż pełne podsumowanie

The AOK NordWest offers drug discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for multiple active ingredients via an open-house procedure. This is not a public procurement under EU directives but is published for transparency. Qualified pharmaceutical companies can join at any time until the deadline. Contracts start no earlier than 01.07.2025, with a maximum duration of 24 months. No exclusivity is granted; future exclusive contracts may suspend these agreements.

Ryzyka

The buyer reserves the right to conclude exclusive contracts during the term, which will suspend these open-house agree...

No guaranteed purchase volumes; actual revenue depends on prescriptions and market share.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company as defined in §4 Abs. 18 AMG.
  • Must remain a pharmaceutical company for the entire contract duration.

Administrative

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified; all eligible participants receive a contract.

Zamawiający

Lokalizacja

Dortmund, DEU

Identyfikator

DE124159739

Działalność

Health

Części (1)

LOT-0001

Drug discount agreements from 01.07.2025 for various active ingredients under an open-house procedure

Open-house procedure for drug discount agreements on multiple active ingredients (Amifampridin, Axitinib, Clindamycin & Benzoylperoxid, Fluorouracil Kombinationen, Folsäure, Imiquimod, Lamivudin & Tenofovirdisoproxil & Doravirin, Lapatinib, Macrogol, Maraviroc, Mesalazin, Peginterferon alfa-2a, Pegvisomant, Pimecrolimus, Raltegravir, Sevelamerhydrochlorid, Xylometazolin). Uniform terms and conditions. No exclusivity. Continuous accession possible.

SuppliesEU fundedElectronic submission

Lokalizacja

Hagen, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; all eligible participants receive a contract.

Termin

Deadline Apr 26, 2027

Szczegóły zamówienia

Data publikacji
12 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
306881-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3